Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Taysha Gene Therapies's total debt was $49.26M at Jun 30, 2026. For fiscal 2025 it was $50.11M, up 14.0% from the year before. The highest annual figure on record is $50.11M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.11M | +14.0% |
| FY2024 | Dec 31, 2024 | $43.94M | +8.5% |
| FY2023 | Dec 31, 2023 | $40.51M | +6.7% |
| FY2022 | Dec 31, 2022 | $37.97M | +2.1% |
| FY2021 | Dec 31, 2021 | $37.19M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $49.26M | +20.0% |
| Q1 FY2026 | Mar 31, 2026 | $48.96M | +15.3% |
| Q4 FY2025 | Dec 31, 2025 | $50.11M | +14.0% |
| Q3 FY2025 | Sep 30, 2025 | $50.85M | +18.3% |
| Q2 FY2025 | Jun 30, 2025 | $41.05M | +8.5% |
| Q1 FY2025 | Mar 31, 2025 | $42.45M | +4.8% |
| Q4 FY2024 | Dec 31, 2024 | $43.94M | +8.5% |
| Q3 FY2024 | Sep 30, 2024 | $42.97M | +11.5% |
| Q2 FY2024 | Jun 30, 2024 | $37.84M | -1.4% |
| Q1 FY2024 | Mar 31, 2024 | $40.51M | +6.2% |
| Q4 FY2023 | Dec 31, 2023 | $40.51M | +6.7% |
| Q3 FY2023 | Sep 30, 2023 | $38.55M | +2.1% |
| Q2 FY2023 | Jun 30, 2023 | $38.35M | +2.1% |
| Q1 FY2023 | Mar 31, 2023 | $38.16M | +2.1% |
| Q4 FY2022 | Dec 31, 2022 | $37.97M | +2.1% |
| Q3 FY2022 | Sep 30, 2022 | $37.77M | +35.8% |
| Q2 FY2022 | Jun 30, 2022 | $37.58M | – |
| Q1 FY2022 | Mar 31, 2022 | $37.39M | – |
| Q4 FY2021 | Dec 31, 2021 | $37.19M | – |
| Q3 FY2021 | Sep 30, 2021 | $27.81M | – |
See a number that looks wrong?